TICKERNERD
Menu
SCNXSCNXHealthcare · Pharmaceutical Retailers

SCNX Stock Forecast: Scienture Holdings, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026
$3.91
+3.99% on the day

The 1 Wall Street analysts covering Scienture Holdings, Inc. hold a median 12-month price target of $38 — +859.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 12 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.2M
Ticker Nerd rank
7 / 100
Median analyst target
$38
Analysts covering
1
Revenue$344K
Operating income−$2.7M
Net income−$2.8M
Free cash flow−$9.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.4%
1M
−55.1%
YTD
−69.3%
1Y
−77.7%
From 52W high
−94.0%
From 52W low
+5.4%
$4
$65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SCNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Scienture Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026
7 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Revisions
85
Accruals
8
Growth
8
Momentum
7
Value
6
Issuance
4
Quality
3
Volatility
2

Size (94): Smaller than most of the companies we track.

Volatility (2): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SCNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SCNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26SCNXHigh $38Median $38Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $38Median $38High $38

The green dot is the last close — the median target sits +859.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Feb 2026Maxim GroupInitiatesBuy$1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SCNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SCNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 12 Oct 2026, Scienture Holdings, Inc. returned −77.7% against +20.4% for the S&P 500, dividends included.

SCNX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26SCNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SCNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Scienture Holdings, Inc. (SCNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.6×

Cheaper than 71% of US stocks

Price / sales
7.5×

Cheaper than 17% of US stocks

Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
−0.8×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
510.1%

Higher than 98% of US stocks

Earnings growth (YoY)
449.1%

Higher than 95% of US stocks

Gross margin
97.7%

Higher than 99% of US stocks

Operating margin
−785.6%

Higher than 6% of US stocks

Net margin
76.8%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−53.5%

Higher than 21% of US stocks

Return on assets
−8.9%

Higher than 28% of US stocks

Dividend yield
163.0%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Scienture Holdings, Inc. (SCNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Scienture Holdings, Inc. has a market value of $6.2M and an enterprise value of $9.3M.

  • Revenue in the twelve months to 30 June 2026: $821K. The latest quarter grew 510.1% year on year.

  • Net income over the same four quarters: −$38.0M, a −4620.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$15.5M.

  • Shares outstanding: 41.1M.

  • Trailing P/E: 0.6×; forward P/E: −7.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 163.04%, paying out 0% of earnings.

  • Scienture Holdings, Inc. employs 4 people — $205K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

SCNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPharmaceutical Retailers
CompanyMarket capTKN rank
SCNXScienture Holdings, Inc.$6.2M
7
PETSPetMed Express, Inc.$26.9M
47
RDGTChina Jo-Jo Drugstores, Inc. /Old/$798,900.00
22
WOKWORK Medical Technology Group Ltd.*$6.4M
16
HCTIHealthcare Triangle, Inc.*$6.5M
22
ACONAclarion, Inc.*$6.5M
29
TRAWTraws Pharma, Inc.*$6.3M
51

* Nearest Healthcare names by size — few pharmaceutical retailers companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Scienture Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SCNX news & analysis

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

GlobeNewsWire · 13 Oct 2026positive

Scienture reported approximately $1.22 million in unaudited preliminary Q3 2026 revenue, a 256% increase sequentially. It attributed growth to continued Arbli sales and REZENOPY's August 2026 commercial launch and initial wholesale shipments.

Why it matters — The update gives SCNX watchers a preliminary view of quarterly revenue growth and the contributions cited from its product sales and launch.

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

GlobeNewsWire · 2 Oct 2026positive

Scienture Holdings announced that Arbli has been added to the formularies of three leading U.S. pediatric academic medical centers and hospitals, a major institutional formulary win that expands Arbli's presence in pediatric care. The company also reported that wholesale orders for the product continue to increase sequentially.

Why it matters — A SCNX watcher would care because gaining placement at three major pediatric academic medical centers and rising wholesale orders signals expanding commercial adoption of the company's Arbli product.

Scienture Holdings, Inc. Announces Reverse Stock Split

GlobeNewsWire · 30 Sept 2026neutral

Scienture Holdings, Inc. announced a 1-for-25 reverse stock split of its outstanding common stock, effective before markets open on October 5, 2026. The stock will continue trading on the Nasdaq Capital Market under the symbol "SCNX" on a split-adjusted basis, with approximately 1,642,565 shares expected outstanding following the split.

Why it matters — This corporate action changes the per-share price and share count of SCNX stock, so a holder would want to understand how the split affects their position and the company's listing.

SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner

GlobeNewsWire · 22 Sept 2026positive

Scienture Holdings announced an agreement with a distribution partner to expand the commercial reach of REZENOPY™ to addiction treatment centers, providing a dedicated commercial channel across approximately 2,000 Opioid Treatment Program clinics and other addiction treatment center networks in the United States.

Why it matters — This expansion could broaden REZENOPY's market access and drive wider adoption among addiction treatment providers.

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

GlobeNewsWire · 9 Sept 2026positive

Scienture Holdings announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. Management is expected to highlight the growing commercial momentum of Arbli and the commercial launch of REZENOPY.

Why it matters — The presentation gives SCNX watchers a chance to hear management discuss the commercial progress of its products at a major investment conference.

FAQ

Frequently asked questions about SCNX stock

What is the SCNX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Scienture Holdings, Inc. have a median 12-month price target of $38, with estimates ranging from $38 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SCNX stock a buy right now?

Of the 1 analysts covering Scienture Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scienture Holdings, Inc. 7 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SCNX?

As at 12 Oct 2026, Scienture Holdings, Inc. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will SCNX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +859.1% from the last close, and Ticker Nerd's factor model ranks Scienture Holdings, Inc. 7 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SCNX stock forecast for 2030?

No analyst covering Scienture Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $38 over the next 12 months.

How has SCNX stock performed over the past year?

Scienture Holdings, Inc. returned -77.7% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Scienture Holdings, Inc. do?

Scienture Holdings, Inc. is a pharmaceutical holding company focused on developing, commercializing, and distributing specialty products that address unmet needs in patient care.

What is the latest news on SCNX?

The most recent item we track (GlobeNewsWire, 13 Oct 2026): "SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth". Scienture reported approximately $1.22 million in unaudited preliminary Q3 2026 revenue, a 256% increase sequentially. It attributed growth to continued Arbli sales and REZENOPY's August 2026 commercial launch and initial wholesale shipments.

Company

About Scienture Holdings, Inc.

Scienture Holdings, Inc. is a pharmaceutical holding company focused on developing, commercializing, and distributing specialty products that address unmet needs in patient care. Through its operating businesses, the company works in areas such as central nervous system and cardiovascular therapies, with an emphasis on novel formulations and delivery systems designed for practical use by physicians, caregivers, and patients. Its current portfolio includes specialty pharmaceutical products and product candidates aimed at improving treatment options in targeted therapeutic categories. Based in Commack, New York, Scienture Holdings serves the healthcare market by combining product development, commercialization, and distribution capabilities within a focused specialty pharmaceutical platform.

CEO Dr. Shankar Hariharan Ph.D. · 4 employees · United States · https://scienture.com